CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: A Children's Cancer Group study

Blood

Volumn 88, Issue 11, 1996, Pages 4288-4295

  Uckun, Fatih M ^a,b   Steinherz, Peter G ^c   Sather, Harland ^c   Trigg, Michael ^c   Arthur, Diane ^c   Tubergen, David ^c   Gaynon, Paul ^c   Reaman, Gregory ^c  

^a The Leukemia & Lymphoma Society   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CD2 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; LEUKEMIA CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 0029995688     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.11.4288.4288     Document Type: Article

References (49)

1. Greaves MF: Differentiation linked leukemogenesis in lymphocytes. Science 234:697, 1986
2. Champlin, R. Gale RP: Acute lymphoblastic leukemia: Recent advances in biology and therapy. Blood 73:2051, 1989
3. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn E, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallon SE, Sather H, Shuster J, Simon R, Trigg M, Uckun F, Ungerleider R: A uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia (ALL). J Clin Oncol 14:18, 1996
4. Shorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740, 1994
5. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Arthur DC, George SL, Bloomfield CD, Schiffer CA: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood 85:2025, 1995
6. Hoelzer D, Tiel E, Löffler, Büchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Rühl H, Maschmeyer G, Lipp T, Nowrousian MR, Burkert M, Gerecke D, Pralle H, Müller U, Lunscken Ch, Fülle H, Ho AD, Küchler R, Busch FW, Schneider W, Görg Ch. Emmerich B, Braumann D, Vaupel HA, von Paleske A, Bartels H, Neiss A, Messerer D: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71:123, 1988
7. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122, 1994
8. Trigg ME, Gaynon P, Uckun FM. Acute lymphoblastic leukemia in children, in Holland JF, Fry E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds): Cancer Medicine (ed 4). Philadelphia, PA, Williams & Wilkins, 1996, p 1
9. Foon KA, Todd RF III: Immunologic classification of leukemia and lymphoma. Blood 68:1, 1986
10. Pui CH. Childhood leukemias. New Engl J Med 332:1618, 1995
11. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF: Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T cell lineage. Proc Natl Acad Sci USA 77:1588, 1980
12. Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE: Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A Pediatric Oncology Group Study. Blood 72:1891, 1988
13. Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M: Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 75:166, 1990
14. Pui CH, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, Kalwinsky DK, Sandlund JT, Crist WM, Raimondi SC: Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75:174, 1990
15. Pullen DJ, Sullivan MP, Faletta JM, Boyett JM, Humphrey GB, Starling KA, Land VJ, Dyment PG, Vats T, Duncan MH: Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: Results and prognostic factors (A Pediatric Oncology Group Study). Blood 60:1159, 1982
16. Borowitz MJ, Dowell ML, Boyett JM, Pullen J, Crist WM, Quddus FM, Falletta JM, Metzgar RS: Clinicopathologic aspects of E rosette negative T-cell acute lymphocytic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 4:170, 1986
17. Uckun FM, Reaman G, Steinherz PG, Sather H, Trigg M, Tubergen D, Gaynon P: Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: A Children's Cancer Group Study. Leuk Lymphoma (in press)
18. Gaynon P, Steinherz P, Bleyer WA, Ablin A, Albo V, Finkelstein J, Grossman N, Littman P, Novak L, Pyesmany A, Reaman G, Sather H, Hammond D: Intensive therapy for children with acute lymphoblastic leukemia and unfavorable presenting features. Lancet 2:921, 1988
19. Steinherz P, Gaynon P, Miller D, Reaman G, Bleyer WA, Finkelstein J, Evans R, Meyers P, Steinherz L, Sather H, Hammond D: Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York Regimen - A new intensive therapy protocol. J Clin Oncol 4:744, 1986
20. Tubergen D, Gilchrist G, O'Brien R, Coccia P, Sather H, Waskerwitz M, Hammond D: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 11:527, 1993
21. Uckun FM, Myers DE, Jaszcz W, Haissig S, Gajl-Peczalska K, Ledbetter JA: Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 76:2449, 1990
22. Uckun FM, Gajl-Peczalska KJ, Provisor AJ, Heerema NA: Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. Blood 73:271, 1989
23. Uckun FM, Ledbetter JA: Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci USA 85:8603, 1988
24. Uckun FM, Gajl-Peczalska KJ, Ledbetter JA, Koller B: Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 73:1000, 1989
25. Gaynon P, Steinherz P, Bleyer WA, Ablin A, Albo V, Finkelstein J, Grossman N, Novak L, Pyesmany A, Reaman G, Chappell R, Sather H, Hammond D: Improved therapy for children with acute lymphoblastic leukemia and unfavorable features: A follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol 11:2234, 1993
26. Gaynon PA, Bostrom B, Reaman G, Sather H, Trigg ME, Tebergen DG, Uckun FM: Childrens Cancer Group (CCG) initiatives in childhood acute lymphoblastic leukemia (ALL). Int J Pediatr Hematol Oncol (in press)
27. Tubergen, D, Gilchrest G, O'Brien R, Coccia P, Sather H, Waskerwitz M, Hammond D: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 11:527, 1993
28. Gaynon P, Bleyer WA, Steinherz P, Finkelstein J, Littman P, Miller D, Reaman G, Sather H, Hammond D: Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable features. Am J Pediatr Hematol Oncol 10:42, 1988
29. Tubergen D, Gilchrist G, O'Brien R, Coccia P, Sather H, Waskerwitz M, Hammond D: Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy. J Clin Oncol 11:520, 1993
30. Cherlow J, Steinherz P, Sather H, Gaynon P, Grossman N, Kersey J, Maurer H, Brenneman J, Trigg M, Hammond D: The role of radiation therapy in the treatment of acute lymphocytic leukemia with lymphomatous presentation. Int J Radiat Oncol Biol Phy 27:1001, 1993
31. Reaman G, Feusner J, Heerema N, Steinherz PG, Zeltzer P, Bleyer WA, Sather H, Hammond GD: Intensive systemic and intrathecal chemotherapy improves the outcome for infants with acute lymphoblastic leukemia. Proc Am Soc Clin Oncol 8:211, 1989 (abstr 821)
32. Trigg M, Gaynon P, Reaman G, Steinherz P, Sather H: Treatment strategy for children with acute lymphoblastic leukemia and unfavorable features: CCG studies, in Kimura K, Yamada K, Carter SK, Longo DL (eds): Cancer Chemotherapy: Challenges for the Future (vol 8). International Congress Series No. 1048, Proceedings of the 8th Nagoya International Symposium on Cancer Treatment, Tokyo, Japan, Excerpta Medica, 1993, p 260
33. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
34. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
35. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PA: Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II. Analysis and examples. Br J Cancer 35:1, 1977
36. Breslow N: Analysis of survival data under the proportional hazards model. Int Stat Rev 43:45, 1975
37. Cox DR: Regression models and life tables. J R Stat Soc B 34:187, 1972
38. Thomas D, Breslow N, Gart J: Trend and homogeneity analyses of proportions and life table data. Comput Biomed Res 10:373, 1977
39. Denning SM: CD2 cluster report, in Schlossman SF, Bounsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF (eds): Leukocyte Typing V: White Cell Differentiation Antigens (vol 1). Oxford, UK, Oxford University Press, 1995, p 342
40. Lobach DF, Hensley LL, Ho W, Haynes BF: Human T cell antigen expression during the early stages of fetal thymic maturation. J Immunol 135:1752, 1985
41. Bowden G, Diaz LA, Li LL, Fox DA: Epitopes and functional responses defined by workshop anti-CD2 in monoclonal antibodies, in Schlossman SF, Bounsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF (eds): Leukocyte Typing V: White Cell Differentiation Antigens (vol 1). Oxford, UK, Oxford University Press, 1995, p 346
42. Schraven B, Kirchgessner H, Meuer SC: Two-dimensional gel electrophoresis analysis of the CD2 molecular complex: Evidence of CD2 association with an 85 kDa component of the p59fyn molecular complex and a novel CD3/Ti associated dimer, in Schlossman SF, Bounsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF (eds): Leukocyte Typing V: White Cell Differentiation Antigens (vol 1). Oxford, UK, Oxford University Press, 1995, p 350
43. Meuer SC, Samstag Y, Schraven B: Accessory signals for growth and differentiation of human T lymphocytes. Cancer Surv 22:63, 1995
44. Ledbetter JA, Schieven GL, Kuebelbeck VM, Uckun FM: Accessory receptors regulate coupling of the T cell receptor complex to tyrosine kinase activation and mobilization of cytoplasmic calcium in T-lineage acute lymphoblastic leukemia. Blood 77:1271, 1991
45. Uckun FM, Tuel-Ahlgren L, Song CW, Waddick KG, Myers DE, Kirihara J, Ledbetter JA, Schieven GL: Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death. Proc Natl Acad Sci USA 89:9005, 1992
46. Eischen CM, Dick CJ, Leibson PJ: Tyrosine kinase activation provides an early and requisite signal for Fas-induced apoptosis. J Immunol 153:1947, 1994
47. Uckun FM, Reaman GH: Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma 18:195, 1995
48. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Tuel-Ahlgren L, Chelstrom LM, Burkhardt A, Bolen J, Myers DE: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267:886, 1995
49. Myers DE, Jun X, Waddick KG, Chelstrom LM, Gunther R, Bolen J, Uckun FM: Membrane-associated CD19-Lyn complex is an endogenous p53-independent and bcl-2 independent regulator of apoptosis in human B-lineage lymphoma cells. Proc Natl Acad Sci USA 92:9575, 1995